<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background </plain></SENT>
<SENT sid="1" pm="."><plain>Self-expanding metal stents can alleviate malignant <z:e sem="disease" ids="C0235328" disease_type="Disease or Syndrome" abbrv="">colonic obstruction</z:e> in incurable patients and avoid palliative stoma surgery </plain></SENT>
<SENT sid="2" pm="."><plain>Objective </plain></SENT>
<SENT sid="3" pm="."><plain>Evaluate stent effectiveness and safety on palliation of patients with malignant colorectal strictures </plain></SENT>
<SENT sid="4" pm="."><plain>Design </plain></SENT>
<SENT sid="5" pm="."><plain>Two prospective, one Spanish and one global, multicenter studies </plain></SENT>
<SENT sid="6" pm="."><plain>Settings </plain></SENT>
<SENT sid="7" pm="."><plain>39 centers (22 academic, 17 community hospitals) from 13 countries </plain></SENT>
<SENT sid="8" pm="."><plain>Patients </plain></SENT>
<SENT sid="9" pm="."><plain>A total of 257 patients were enrolled, and 255 patients were treated with a WallFlex uncovered enteral colonic stent </plain></SENT>
<SENT sid="10" pm="."><plain>Follow-up was up to 12 months or until <z:hpo ids='HP_0011420'>death</z:hpo> or retreatment </plain></SENT>
<SENT sid="11" pm="."><plain>Interventions(s) </plain></SENT>
<SENT sid="12" pm="."><plain>Self-expanding metal stent placement </plain></SENT>
<SENT sid="13" pm="."><plain>Main Outcome Measures </plain></SENT>
<SENT sid="14" pm="."><plain>Procedural success, clinical success, and safety </plain></SENT>
<SENT sid="15" pm="."><plain>Results </plain></SENT>
<SENT sid="16" pm="."><plain>Procedural success was 98.4% (251) </plain></SENT>
<SENT sid="17" pm="."><plain>Clinical success rates were 87.8% at 30 days, 89.7% at 3 months, 92.8% at 6 months, and 96% at 12 months </plain></SENT>
<SENT sid="18" pm="."><plain>Overall <z:mpath ids='MPATH_81'>perforation</z:mpath> rate was 5.1% </plain></SENT>
<SENT sid="19" pm="."><plain>Overall migration rate was 5.5% </plain></SENT>
<SENT sid="20" pm="."><plain>Overall <z:hpo ids='HP_0011420'>death</z:hpo> rate during follow-up was 48.6% (124), with 67.7% of <z:hpo ids='HP_0011420'>deaths</z:hpo> related to the patient's <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, unrelated in 32.3% </plain></SENT>
<SENT sid="21" pm="."><plain>Only 2 <z:hpo ids='HP_0011420'>deaths</z:hpo> were related to the stent or procedure </plain></SENT>
<SENT sid="22" pm="."><plain>Limitations </plain></SENT>
<SENT sid="23" pm="."><plain>No control group </plain></SENT>
<SENT sid="24" pm="."><plain>Conclusions </plain></SENT>
<SENT sid="25" pm="."><plain>The primary palliative option for patients with malignant <z:e sem="disease" ids="C0235328" disease_type="Disease or Syndrome" abbrv="">colonic obstruction</z:e> should be self-expanding metal stent placement due to high rates of technical success and efficacy in symptom palliation and few complications </plain></SENT>
</text></document>